{"id":360,"date":"2024-09-26T14:14:10","date_gmt":"2024-09-26T14:14:10","guid":{"rendered":"https:\/\/stgmevpro.wpenginepowered.com\/?page_id=360"},"modified":"2025-09-08T12:43:54","modified_gmt":"2025-09-08T12:43:54","slug":"trial-hcp","status":"publish","type":"page","link":"https:\/\/mevproclinicaltrials.com\/pl-pl\/trial-hcp\/","title":{"rendered":"Trial HCP"},"content":{"rendered":"<div data-elementor-type=\"wp-page\" data-elementor-id=\"360\" class=\"elementor elementor-360\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-00e60df header-background e-flex e-con-boxed e-con e-parent\" data-id=\"00e60df\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-37dd70f e-con-full e-flex e-con e-child\" data-id=\"37dd70f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b3cf64b elementor-widget__width-initial elementor-widget-tablet__width-inherit elementor-widget elementor-widget-heading\" data-id=\"b3cf64b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Informacje o badaniach klinicznych MEVPRO dotycz\u0105cych raka gruczo\u0142u krokowego firmy Pfizer<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d8b7b5d hero-heading elementor-widget__width-initial elementor-widget-mobile__width-inherit elementor-widget-tablet__width-inherit elementor-widget elementor-widget-heading\" data-id=\"d8b7b5d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Pomoc w rozwoju bada\u0144 dotycz\u0105cych leczenia raka gruczo\u0142u krokowego<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-28b8308 e-con-full e-flex e-con e-child\" data-id=\"28b8308\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-272fb55 e-flex e-con-boxed e-con e-parent\" data-id=\"272fb55\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-24e7439 elementor-widget elementor-widget-heading\" data-id=\"24e7439\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Badania kliniczne MEVPRO firmy Pfizer stanowi\u0105 potencjaln\u0105 opcj\u0119 leczenia Pa\u0144stwa pacjent\u00f3w<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-357189b4 smalltrial e-flex e-con-boxed e-con e-parent\" data-id=\"357189b4\" data-element_type=\"container\" data-e-type=\"container\" id=\"MEVPRO-1\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-564190de e-con-full e-flex e-con e-child\" data-id=\"564190de\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5211ffb1 elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"5211ffb1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M8 8L15.5 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><path d=\"M15.5 8L8 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Jeszcze nie ma naboru<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-88646db elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"88646db\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M10 7L14.5 11.5L10 16\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Trwa nab\u00f3r<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1be04a7e textBreast elementor-widget elementor-widget-text-editor\" data-id=\"1be04a7e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-1\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-54b00164 elementor-widget elementor-widget-text-editor\" data-id=\"54b00164\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tDla Pa\u0144stwa pacjent\u00f3w z przerzutowym rakiem gruczo\u0142u krokowego opornym na abirateron\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-12eb84b2 elementor-align-left elementor-widget elementor-widget-button\" data-id=\"12eb84b2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06551324?term=NCT06551324&#038;rank=1\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrials.gov<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1a8227d1 elementor-align-left elementor-widget elementor-widget-button\" data-id=\"1a8227d1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&#038;EUCT=2024-511650-50-00\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrialsregister.eu<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-7103bdce e-con-full e-flex e-con e-child\" data-id=\"7103bdce\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-31ed7ff5 elementor-widget elementor-widget-image\" data-id=\"31ed7ff5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"111\" height=\"76\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/10\/result-1.svg\" class=\"attachment-full size-full wp-image-442\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6e216dc7 elementor-widget elementor-widget-text-editor\" data-id=\"6e216dc7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tBadanie kliniczne fazy III oceniaj\u0105ce dzia\u0142anie badanego leku (mevrometostat) w skojarzeniu z enzalutamidem w por\u00f3wnaniu z enzalutamidem lub docetakselem stosowanym w monoterapii u doros\u0142ych pacjent\u00f3w z przerzutowym opornym na kastracj\u0119 rakiem gruczo\u0142u krokowego (mCRPC) uprzednio leczonych octanem abiraterononu.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-59482efa learn-more mevpro1Tile elementor-widget elementor-widget-button\" data-id=\"59482efa\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"morebtn5\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-right\" viewbox=\"0 0 320 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Wi\u0119cej informacji<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6cfadaa8 learn-more mevpro1Tile elementor-widget elementor-widget-button\" data-id=\"6cfadaa8\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"morebtnopen5\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-down\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M207.029 381.476L12.686 187.132c-9.373-9.373-9.373-24.569 0-33.941l22.667-22.667c9.357-9.357 24.522-9.375 33.901-.04L224 284.505l154.745-154.021c9.379-9.335 24.544-9.317 33.901.04l22.667 22.667c9.373 9.373 9.373 24.569 0 33.941L240.971 381.476c-9.373 9.372-24.569 9.372-33.942 0z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Wi\u0119cej informacji<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6c27029f elementor-widget elementor-widget-html\" data-id=\"6c27029f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\n    document.getElementById(\"morebtn5\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo5\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn5\").style.display = \"none\";\n      document.getElementById(\"morebtnopen5\").style.display = \"block\";\n    };\n  \n    document.getElementById(\"morebtnopen5\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo5\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn5\").style.display = \"block\";\n      document.getElementById(\"morebtnopen5\").style.display = \"none\";\n    };\n  <\/script>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-7c176cc9 bigtrial e-flex e-con-boxed e-con e-parent\" data-id=\"7c176cc9\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-695a13a0 detailsveritac elementor-widget elementor-widget-template\" data-id=\"695a13a0\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"moreinfo5\" data-widget_type=\"template.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-template\">\n\t\t\t\t\t<div data-elementor-type=\"container\" data-elementor-id=\"447\" class=\"elementor elementor-447\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t<div class=\"elementor-element elementor-element-27aa089b detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"27aa089b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f7b7d90 elementor-widget elementor-widget-text-editor\" data-id=\"f7b7d90\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tSzczeg\u00f3\u0142y badania\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1d10ba88 elementor-widget elementor-widget-text-editor\" data-id=\"1d10ba88\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-1 is a Phase 3, randomized, open-label clinical trial to evaluate an investigational medicine called mevrometostat for men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed after treatment with abiraterone acetate. MEVPRO-1 will investigate whether mevrometostat in combination with enzalutamide is superior to either enzalutamide or docetaxel in prolonging radiographic progression-free survival in the mCRPC setting.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-30600248 elementor-widget elementor-widget-text-editor\" data-id=\"30600248\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tApproximately 600 participants will be randomly assigned in a 1:1 ratio to Arm A or Arm B.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5c925d11 detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"5c925d11\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-2c3b9a9a e-con-full e-flex e-con e-child\" data-id=\"2c3b9a9a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-80db81b elementor-widget elementor-widget-text-editor\" data-id=\"80db81b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li><span style=\"color: #097900; font-weight: 600;\">Grupa badanego leku A: <\/span><br>Mevrometostat 875 mg BID <span style=\"font-weight: 600;\">plus<\/span><br> enzalutamid 160 mg QD<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-25fdc07 e-con-full e-flex e-con e-child\" data-id=\"25fdc07\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d6e223f elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"d6e223f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><span style=\"color: #097900; font-weight: 600;\">Grupa leku por\u00f3wnawczego B: <\/span><br \/>Wyb\u00f3r wg lekarza prowadz\u0105cego badanie: enzalutamid 160 mg QD <span style=\"font-weight: 600;\">LUB<\/span><br \/>docetaxel 75 mg\/m<sup>2<\/sup> do\u017cylnie w ka\u017cdym cyklu (21 dni) przez maksymalnie 10 cykli.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-22d71a08 e-flex e-con-boxed e-con e-parent\" data-id=\"22d71a08\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2ad7d7cc elementor-widget elementor-widget-text-editor\" data-id=\"2ad7d7cc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tUczestnicy b\u0119d\u0105 przyjmowa\u0107 badane leczenie do czasu post\u0119pu choroby w ocenie radiologicznej, wyst\u0105pienia niedopuszczalnej toksyczno\u015bci, naruszenia protoko\u0142u, wycofania lub zako\u0144czenia badania. Czas udzia\u0142u w badaniu MEVPRO-1 b\u0119dzie zale\u017cny od tolerancji badanego leczenia przez uczestnik\u00f3w lub od czasu do post\u0119pu choroby. \n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e7b51a elementor-widget elementor-widget-text-editor\" data-id=\"4e7b51a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tThe study includes a 28-day screening period, the treatment period, and a 28- to 35-day safety follow-up. The treatment period in the study will consist of cycles of 3 weeks (docetaxel group) or 4 weeks (enzalutamide groups). Participants receiving investigational mevrometostat and enzalutamide or enzalutamide alone will attend 2 study visits in Cycles 1 and 2, then 1 study visit per cycle thereafter. Participants receiving standard-of-care docetaxel will attend 1 study visit per cycle for up to 10 cycles. \n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-024c71f elementor-widget elementor-widget-text-editor\" data-id=\"024c71f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tLong-term safety follow-up will consist of visits every 12 weeks from the last dose until the study is complete, which may take many years, or until the participant withdraws consent.\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4445dbb5 e-con-full e-flex e-con e-parent\" data-id=\"4445dbb5\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-610b58e0 elementor-widget elementor-widget-text-editor\" data-id=\"610b58e0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tUczestnicy kwalifikuj\u0105cy si\u0119 do udzia\u0142u w badaniu \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5f8244e5 elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"5f8244e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"37\" height=\"38\" viewbox=\"0 0 37 38\" fill=\"none\"><path d=\"M35.8058 19.1635C35.8058 28.7761 28.0143 36.5685 18.4029 36.5685C8.79155 36.5685 1 28.7761 1 19.1635C1 9.55103 8.79155 1.75854 18.4029 1.75854\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M34.4319 4.04865L18.4029 23.5148L11.0753 17.5604\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Kluczowe kryteria w\u0142\u0105czenia:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3419d371 elementor-widget elementor-widget-text-editor\" data-id=\"3419d371\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li>Uczestnicy p\u0142ci m\u0119skiej w wieku \u2265 18 lat w momencie bada\u0144 przesiewowych.\n<\/li>\n \t<li>Histologicznie lub cytologiczne potwierdzony gruczolakorak gruczo\u0142u krokowego bez cech drobnokom\u00f3rkowych. \n<\/li>\n\n \t<li>Choroba przerzutowa do ko\u015bci, potwierdzona w badaniu obrazowym ko\u015bci lub do tkanek mi\u0119kkich, potwierdzona w badaniu TK\/MRI. \n<\/li>\n \t<li>Evidence of disease progression on or after treatment with at least 12 weeks of abiraterone acetate in the metastatic castration-sensitive prostate (mCSPC) cancer or first-line mCRPC setting.\n<\/li>\n\n\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3253b30c elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"3253b30c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"38\" height=\"39\" viewbox=\"0 0 38 39\" fill=\"none\"><path d=\"M36.7946 19.2892C36.7946 29.4096 28.7624 37.5785 18.8973 37.5785C9.03215 37.5785 1 29.4096 1 19.2892C1 9.16892 9.03215 1 18.8973 1C28.7624 1 36.7946 9.16892 36.7946 19.2892Z\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M9.94592 9.64453L28.3459 28.9338\" stroke=\"#097900\" stroke-width=\"2\"><\/path><path d=\"M28.5946 9.89832L9.69731 28.6799\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Kluczowe kryteria wy\u0142\u0105czenia:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-39687a30 elementor-widget elementor-widget-text-editor\" data-id=\"39687a30\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li>Treatment with chemotherapy since becoming castration-resistant.\n<\/li>\n \t<li>Wyst\u0105pienie jakiegokolwiek innego raka w wywiadzie w ci\u0105gu ostatnich 3 lat (poza niekt\u00f3rymi nowotworami sk\u00f3ry lub nowotworami we wczesnym stadium, kt\u00f3re zosta\u0142y wyleczone).\n<\/li>\n \t<li>Klinicznie istotna choroba uk\u0142adu sercowo-naczyniowego, choroba nerek lub choroba w\u0105troby.\n<\/li>\n \t<li>Uprzednie leczenie raka gruczo\u0142u krokowego w dowolnym stadium jak\u0105kolwiek chemioterapi\u0105 lekami cytostatycznymi, terapi\u0105 radioligandami, ARSi (w tym enzalutamid, apalutamid, darolutamid), PARP w monoterapii lub inne og\u00f3lnoustrojowe leczenie przeciwnowotworowe.\n<\/li>\n \t<li>Powa\u017cna operacja lub paliatywna radioterapia miejscowa w ci\u0105gu 14 dni przed randomizacj\u0105.\n<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-713f9797 e-flex e-con-boxed e-con e-parent\" data-id=\"713f9797\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2f78d127 elementor-widget elementor-widget-text-editor\" data-id=\"2f78d127\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Aby uzyska\u0107 informacje na temat wszystkich kryteri\u00f3w kwalifikacji, nale\u017cy porozmawia\u0107 z zespo\u0142em prowadz\u0105cym badanie lub przedstawicielem ds. medycznych firmy Pfizer.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-22c06a92 elementor-widget elementor-widget-text-editor\" data-id=\"22c06a92\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<span style=\"font-weight: 600;\">Dzi\u0119kujemy za rozwa\u017cenie mo\u017cliwo\u015bci udzia\u0142u Pa\u0144stwa pacjent\u00f3w w tym badaniu klinicznym.<\/span>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4990c650 elementor-align-right IDs-btn elementor-widget elementor-widget-button\" data-id=\"4990c650\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"closebtn\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#MEVPRO-1\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"42\" height=\"42\" viewbox=\"0 0 42 42\" fill=\"none\"><circle cx=\"21\" cy=\"21\" r=\"21\" fill=\"#097900\"><\/circle><path d=\"M13 24L21 16L29 24\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3c3ac92f elementor-widget elementor-widget-html\" data-id=\"3c3ac92f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\n    document.addEventListener(\"DOMContentLoaded\", function() {\n      document.getElementById(\"closebtn\").onclick = function() {\n        var moreInfoSection = document.getElementById(\"moreinfo\");\n        moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n        \/\/ Toggle visibility of morebtn and morebtnopen\n        document.getElementById(\"morebtn\").style.display = \"block\";\n        document.getElementById(\"morebtnopen\").style.display = \"none\";\n      };\n  \n      document.getElementById(\"morebtnopen\").onclick = function() {\n        var moreInfoSection = document.getElementById(\"moreinfo\");\n        moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n        \/\/ Toggle visibility of morebtn and morebtnopen\n        document.getElementById(\"morebtn\").style.display = \"block\";\n        document.getElementById(\"morebtnopen\").style.display = \"none\";\n      };\n    });\n  <\/script>\n  \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4d6b27e1 smalltrial e-flex e-con-boxed e-con e-parent\" data-id=\"4d6b27e1\" data-element_type=\"container\" data-e-type=\"container\" id=\"MEVPRO-2\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-7e5f1952 e-con-full e-flex e-con e-child\" data-id=\"7e5f1952\" data-element_type=\"container\" data-e-type=\"container\" id=\"tactiveugov\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6939f0d0 elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"6939f0d0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M8 8L15.5 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><path d=\"M15.5 8L8 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Jeszcze nie ma naboru<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d1cd2fd elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"d1cd2fd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M10 7L14.5 11.5L10 16\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Trwa nab\u00f3r<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b223d4f textBreast elementor-widget elementor-widget-text-editor\" data-id=\"b223d4f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-2\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-24d09b05 elementor-widget elementor-widget-text-editor\" data-id=\"24d09b05\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tFor your patients who have not tried hormonal therapy or chemotherapy for metastatic castrate-resistant prostate cancer\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2880ba5a elementor-align-left elementor-widget elementor-widget-button\" data-id=\"2880ba5a\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"govtactive\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06629779?term=NCT06629779%20&#038;rank=1\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrials.gov<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3075cce8 elementor-align-left elementor-widget elementor-widget-button\" data-id=\"3075cce8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&#038;EUCT=2024-511652-40-00\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrialsregister.eu<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-1b8f53e e-con-full e-flex e-con e-child\" data-id=\"1b8f53e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-52ca76b6 elementor-widget elementor-widget-image\" data-id=\"52ca76b6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"111\" height=\"76\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/10\/result-1.svg\" class=\"attachment-full size-full wp-image-442\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2f482ba8 elementor-widget elementor-widget-text-editor\" data-id=\"2f482ba8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tA Phase 3 clinical trial evaluating the investigational medicine (mevrometostat) in combination with enzalutamide compared to a placebo in combination with enzalutamide in adults with mCRPC who have not tried hormonal therapy or chemotherapy in the castrate-resistant setting. \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bcc563d learn-more mevpro2Tile elementor-widget elementor-widget-button\" data-id=\"bcc563d\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"morebtn4\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-right\" viewbox=\"0 0 320 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Wi\u0119cej informacji<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-41caf536 learn-more mevpro2Tile elementor-widget elementor-widget-button\" data-id=\"41caf536\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"morebtnopen3\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-down\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M207.029 381.476L12.686 187.132c-9.373-9.373-9.373-24.569 0-33.941l22.667-22.667c9.357-9.357 24.522-9.375 33.901-.04L224 284.505l154.745-154.021c9.379-9.335 24.544-9.317 33.901.04l22.667 22.667c9.373 9.373 9.373 24.569 0 33.941L240.971 381.476c-9.373 9.372-24.569 9.372-33.942 0z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Wi\u0119cej informacji<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-355fbbde elementor-widget elementor-widget-html\" data-id=\"355fbbde\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\n    document.getElementById(\"morebtn4\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo4\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn4\").style.display = \"none\";\n      document.getElementById(\"morebtnopen3\").style.display = \"block\";\n    };\n  \n    document.getElementById(\"morebtnopen3\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo4\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn4\").style.display = \"block\";\n      document.getElementById(\"morebtnopen3\").style.display = \"none\";\n    };\n  <\/script>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-2f15f81b bigtrial2 e-flex e-con-boxed e-con e-parent\" data-id=\"2f15f81b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-58d9eadb detailsveritac elementor-widget elementor-widget-template\" data-id=\"58d9eadb\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"moreinfo4\" data-widget_type=\"template.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-template\">\n\t\t\t\t\t<div data-elementor-type=\"container\" data-elementor-id=\"457\" class=\"elementor elementor-457\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t<div class=\"elementor-element elementor-element-27aa089b detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"27aa089b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f7b7d90 elementor-widget elementor-widget-text-editor\" data-id=\"f7b7d90\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tSzczeg\u00f3\u0142y badania\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1d10ba88 elementor-widget elementor-widget-text-editor\" data-id=\"1d10ba88\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-2 is a Phase 3, randomized, double-blind clinical trial of an investigational medicine called mevrometostat in combination with enzalutamide compared to a placebo in combination with enzalutamide in adults with mCRPC (metastatic castration resistant prostate cancer). \n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-912f2e9 elementor-widget elementor-widget-text-editor\" data-id=\"912f2e9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-2 will investigate whether mevrometostat plus enzalutamide can delay or prevent anti-androgen resistance to provide superior clinical benefit compared to enzalutamide alone in participants with mCRPC who have not tried hormonal therapy or chemotherapy in the castrate-resistant setting.\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-30600248 elementor-widget elementor-widget-text-editor\" data-id=\"30600248\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tApproximately 900 participants will be randomly assigned in a 1:1 ratio to Arm A or Arm B.\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5c925d11 detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"5c925d11\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-2c3b9a9a e-con-full e-flex e-con e-child\" data-id=\"2c3b9a9a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-80db81b elementor-widget elementor-widget-text-editor\" data-id=\"80db81b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><span style=\"color: #097900; font-weight: 600;\">Grupa badanego leku A: <\/span><br \/>Mevrometostat 875 mg BID <span style=\"font-weight: 600;\">plus<\/span><br \/>enzalutamide 160 mg<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-25fdc07 e-con-full e-flex e-con e-child\" data-id=\"25fdc07\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d6e223f elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"d6e223f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li><span style=\"color: #097900; font-weight: 600;\">Grupa leku por\u00f3wnawczego B: <\/span><br>\nTabletki placebo BID <span style=\"font-weight: 600;\">plus<\/span>\nenzalutamid 160 mg QD<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-22d71a08 e-flex e-con-boxed e-con e-parent\" data-id=\"22d71a08\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2ad7d7cc elementor-widget elementor-widget-text-editor\" data-id=\"2ad7d7cc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tParticipants will receive investigational treatment until radiographic disease progression, unacceptable toxicity, protocol violation, withdrawal, or study termination. The length of participation in MEVPRO-2 will vary depending on how well participants tolerate the study treatment or time to disease progression. \n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e7b51a elementor-widget elementor-widget-text-editor\" data-id=\"4e7b51a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tThe study includes a 28-day screening period, the treatment period, and a 28 to 35-day safety follow-up. The treatment period in the study will consist of cycles every 28 days. Participants will attend visits every 2 weeks until week 9, then every 4 weeks until week 53, and then every 8 weeks while receiving the study medicine. \n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-024c71f elementor-widget elementor-widget-text-editor\" data-id=\"024c71f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tLong-term safety follow-up will consist of visits every 12 weeks from the last dose until the study is complete, which may take many years, or until the participant withdraws consent.\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4445dbb5 e-con-full e-flex e-con e-parent\" data-id=\"4445dbb5\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-610b58e0 elementor-widget elementor-widget-text-editor\" data-id=\"610b58e0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tUczestnicy kwalifikuj\u0105cy si\u0119 do udzia\u0142u w badaniu \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5f8244e5 elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"5f8244e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"37\" height=\"38\" viewbox=\"0 0 37 38\" fill=\"none\"><path d=\"M35.8058 19.1635C35.8058 28.7761 28.0143 36.5685 18.4029 36.5685C8.79155 36.5685 1 28.7761 1 19.1635C1 9.55103 8.79155 1.75854 18.4029 1.75854\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M34.4319 4.04865L18.4029 23.5148L11.0753 17.5604\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Kluczowe kryteria w\u0142\u0105czenia:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3419d371 elementor-widget elementor-widget-text-editor\" data-id=\"3419d371\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li>Uczestnicy p\u0142ci m\u0119skiej w wieku \u2265 18 lat w momencie bada\u0144 przesiewowych.\n<\/li>\n \t<li>Histologicznie lub cytologiczne potwierdzony gruczolakorak gruczo\u0142u krokowego bez cech drobnokom\u00f3rkowych.<\/li>\n \t<li>Choroba przerzutowa do ko\u015bci, potwierdzona w badaniu obrazowym ko\u015bci lub do tkanek mi\u0119kkich, potwierdzona w badaniu TK\/MRI.\u00a0<\/li>\n \t<li>Progressive disease in the setting of medical or surgical castration as defined by meeting 1 or more of the following 3 criteria:<ul><li>PSA progression defined by a minimum of two rising PSA levels with an interval of \u22651 week between each determination, with a PSA value at the Screening visit being \u22652 \u03bcg\/L.<\/li>\n<li>Soft tissue disease progression as defined by RECIST 1.1.<\/li>\n<li>Post\u0119p choroby ko\u015bci zdefiniowany przez PCWG3 z co najmniej 2 nowymi zmianami przerzutowymi do ko\u015bci w badaniu ko\u015bci ca\u0142ego cia\u0142a z zastosowaniem radioizotop\u00f3w.<\/li><\/ul><\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3253b30c elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"3253b30c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"38\" height=\"39\" viewbox=\"0 0 38 39\" fill=\"none\"><path d=\"M36.7946 19.2892C36.7946 29.4096 28.7624 37.5785 18.8973 37.5785C9.03215 37.5785 1 29.4096 1 19.2892C1 9.16892 9.03215 1 18.8973 1C28.7624 1 36.7946 9.16892 36.7946 19.2892Z\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M9.94592 9.64453L28.3459 28.9338\" stroke=\"#097900\" stroke-width=\"2\"><\/path><path d=\"M28.5946 9.89832L9.69731 28.6799\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Kluczowe kryteria wy\u0142\u0105czenia:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-39687a30 elementor-widget elementor-widget-text-editor\" data-id=\"39687a30\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li>Participants must be treatment na\u00efve at the mCRPC stage, e.g., participants cannot have received any cytotoxic chemotherapy (includes but not limited to docetaxel), received ARSI\/ abiraterone acetate in mCRPC, mCSPC or non-metastatic PC. Prior docetaxel in mCSPC is allowed.\n<\/li>\n \t<li>Wyst\u0105pienie jakiegokolwiek innego raka w wywiadzie w ci\u0105gu ostatnich 3 lat (poza niekt\u00f3rymi nowotworami sk\u00f3ry lub nowotworami we wczesnym stadium, kt\u00f3re zosta\u0142y wyleczone).\n<\/li>\n \t<li>Klinicznie istotna choroba uk\u0142adu sercowo-naczyniowego, choroba nerek lub choroba w\u0105troby.\n<\/li>\n \t<li>Uprzednie leczenie raka gruczo\u0142u krokowego w dowolnym stadium jak\u0105kolwiek chemioterapi\u0105 lekami cytostatycznymi, terapi\u0105 radioligandami, ARSi (w tym enzalutamid, apalutamid, darolutamid), PARP w monoterapii lub inne og\u00f3lnoustrojowe leczenie przeciwnowotworowe.\n<\/li>\n \t<li>Powa\u017cna operacja lub paliatywna radioterapia miejscowa w ci\u0105gu 14 dni przed randomizacj\u0105.\n<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-713f9797 e-flex e-con-boxed e-con e-parent\" data-id=\"713f9797\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2f78d127 elementor-widget elementor-widget-text-editor\" data-id=\"2f78d127\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Aby uzyska\u0107 informacje na temat wszystkich kryteri\u00f3w kwalifikacji, nale\u017cy porozmawia\u0107 z zespo\u0142em prowadz\u0105cym badanie lub przedstawicielem ds. medycznych firmy Pfizer.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-22c06a92 elementor-widget elementor-widget-text-editor\" data-id=\"22c06a92\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 600;\">Dzi\u0119kujemy za rozwa\u017cenie mo\u017cliwo\u015bci udzia\u0142u Pa\u0144stwa pacjent\u00f3w w tym badaniu klinicznym.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4990c650 elementor-align-right IDs-btn elementor-widget elementor-widget-button\" data-id=\"4990c650\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"closebtn\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#MEVPRO-2\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"42\" height=\"42\" viewbox=\"0 0 42 42\" fill=\"none\"><circle cx=\"21\" cy=\"21\" r=\"21\" fill=\"#097900\"><\/circle><path d=\"M13 24L21 16L29 24\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3c3ac92f elementor-widget elementor-widget-html\" data-id=\"3c3ac92f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\n    document.addEventListener(\"DOMContentLoaded\", function() {\n      document.getElementById(\"closebtn\").onclick = function() {\n        var moreInfoSection = document.getElementById(\"moreinfo\");\n        moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n        \/\/ Toggle visibility of morebtn and morebtnopen\n        document.getElementById(\"morebtn\").style.display = \"block\";\n        document.getElementById(\"morebtnopen\").style.display = \"none\";\n      };\n  \n      document.getElementById(\"morebtnopen\").onclick = function() {\n        var moreInfoSection = document.getElementById(\"moreinfo\");\n        moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n        \/\/ Toggle visibility of morebtn and morebtnopen\n        document.getElementById(\"morebtn\").style.display = \"block\";\n        document.getElementById(\"morebtnopen\").style.display = \"none\";\n      };\n    });\n  <\/script>\n  \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-26605ec smalltrial e-flex e-con-boxed e-con e-parent\" data-id=\"26605ec\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-a2359a5 e-con-full e-flex e-con e-child\" data-id=\"a2359a5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-bef1867 elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"bef1867\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M8 8L15.5 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><path d=\"M15.5 8L8 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Jeszcze nie ma naboru<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-88680b2 elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"88680b2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M10 7L14.5 11.5L10 16\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Trwa nab\u00f3r<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-15edc24 textBreast elementor-widget elementor-widget-text-editor\" data-id=\"15edc24\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-3 \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f196d8d elementor-widget elementor-widget-text-editor\" data-id=\"f196d8d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tBadanie dla pacjent\u00f3w z przerzutowym rakiem gruczo\u0142u krokowego wra\u017cliwym na kastracj\u0119, kt\u00f3rzy nie byli leczeni z\u202fpowodu raka wra\u017cliwego na kastracj\u0119, z wyj\u0105tkiem terapii deprywacji androgen\u00f3w (chemicznej lub chirurgicznej) \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-47889f4 elementor-align-left elementor-widget elementor-widget-button\" data-id=\"47889f4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrials.gov<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-733b478 elementor-align-left elementor-widget elementor-widget-button\" data-id=\"733b478\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrialsregister.eu<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-71c0648 e-con-full e-flex e-con e-child\" data-id=\"71c0648\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d7e84ba elementor-widget elementor-widget-image\" data-id=\"d7e84ba\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"111\" height=\"76\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/10\/result-1.svg\" class=\"attachment-full size-full wp-image-442\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d83ebaf elementor-widget elementor-widget-text-editor\" data-id=\"d83ebaf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Badanie kliniczne fazy\u202fIII oceniaj\u0105ce dzia\u0142anie badanego leku (mewrometostat) w\u202fskojarzeniu z enzalutamidem w\u202fpor\u00f3wnaniu z\u202fplacebo w skojarzeniu z enzalutamidem u\u202fdoros\u0142ych pacjent\u00f3w z\u202fuprzednio nieleczonym mCSPC.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-117c6c3 learn-more mevpro2Tile elementor-widget elementor-widget-button\" data-id=\"117c6c3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-right\" viewbox=\"0 0 320 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Wi\u0119cej informacji<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-92fbfab learn-more mevpro2Tile elementor-widget elementor-widget-button\" data-id=\"92fbfab\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-down\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M207.029 381.476L12.686 187.132c-9.373-9.373-9.373-24.569 0-33.941l22.667-22.667c9.357-9.357 24.522-9.375 33.901-.04L224 284.505l154.745-154.021c9.379-9.335 24.544-9.317 33.901.04l22.667 22.667c9.373 9.373 9.373 24.569 0 33.941L240.971 381.476c-9.373 9.372-24.569 9.372-33.942 0z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Wi\u0119cej informacji<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0287610 elementor-widget elementor-widget-html\" data-id=\"0287610\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\n    document.getElementById(\"morebtn6\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo55\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn6\").style.display = \"none\";\n      document.getElementById(\"morebtnopen4\").style.display = \"block\";\n    };\n  \n    document.getElementById(\"morebtnopen4\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo55\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn6\").style.display = \"block\";\n      document.getElementById(\"morebtnopen4\").style.display = \"none\";\n    };\n  <\/script>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-1118ae3 bigtrial2 e-flex e-con-boxed e-con e-parent\" data-id=\"1118ae3\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3a0e637 detailsveritac elementor-widget elementor-widget-template\" data-id=\"3a0e637\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"template.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-template\">\n\t\t\t\t\t<div data-elementor-type=\"container\" data-elementor-id=\"587\" class=\"elementor elementor-587\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t<div class=\"elementor-element elementor-element-27aa089b detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"27aa089b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f7b7d90 elementor-widget elementor-widget-text-editor\" data-id=\"f7b7d90\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tSzczeg\u00f3\u0142y badania\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1d10ba88 elementor-widget elementor-widget-text-editor\" data-id=\"1d10ba88\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-3 to randomizowane badanie kliniczne fazy\u202fIII, prowadzone metod\u0105 podw\u00f3jnie \u015blepej pr\u00f3by, oceniaj\u0105ce dzia\u0142anie badanego leku o\u202fnazwie mewrometostat w\u202fskojarzeniu z enzalutamidem w\u202fpor\u00f3wnaniu z placebo w skojarzeniu z enzalutamidem u\u202fdoros\u0142ych pacjent\u00f3w z\u202fmCSPC (przerzutowym rakiem gruczo\u0142u krokowego wra\u017cliwym na kastracj\u0119).\u00a0\u00a0\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-912f2e9 elementor-widget elementor-widget-text-editor\" data-id=\"912f2e9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Badanie MEVPRO-3 ma na celu ocen\u0119 tego, czy stosowanie mewrometostatu w\u202fskojarzeniu z enzalutamidem mo\u017ce spowolni\u0107 lub zapobiec oporno\u015bci na antyandrogeny, zapewniaj\u0105c lepsze korzy\u015bci kliniczne w\u202fpor\u00f3wnaniu z\u202fplacebo w skojarzeniu z\u202fenzalutamidem u\u202fuczestnik\u00f3w z mCSPC uprzednio niestosuj\u0105cych nowej terapii hormonalnej ani chemioterapii w\u202fleczeniu raka gruczo\u0142u krokowego wra\u017cliwego na kastracj\u0119.\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-30600248 elementor-widget elementor-widget-text-editor\" data-id=\"30600248\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tOko\u0142o 1000 uczestnik\u00f3w zostanie losowo przypisanych w\u202fstosunku 1:1 do grupy A lub grupy B.\u00a0\u00a0\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5c925d11 detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"5c925d11\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-2c3b9a9a e-con-full e-flex e-con e-child\" data-id=\"2c3b9a9a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-80db81b elementor-widget elementor-widget-text-editor\" data-id=\"80db81b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li><span style=\"color: #097900; font-weight: 600;\">Grupa badanego leku A: <\/span><br>\nMewrometostat 875\u202fmg dwa razy na dob\u0119 (BID)<br> <span style=\"font-weight: 600;\">plus<\/span>\nenzalutamid 160\u202fmg raz na dob\u0119 (QD)<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-25fdc07 e-con-full e-flex e-con e-child\" data-id=\"25fdc07\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d6e223f elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"d6e223f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li><span style=\"color: #097900; font-weight: 600;\">Grupa kontrolna B:  <\/span><br>\nTabletki placebo BID <span style=\"font-weight: 600;\">plus<\/span>\nenzalutamid 160 mg QD<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-22d71a08 e-flex e-con-boxed e-con e-parent\" data-id=\"22d71a08\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2ad7d7cc elementor-widget elementor-widget-text-editor\" data-id=\"2ad7d7cc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Uczestnicy b\u0119d\u0105 przyjmowa\u0107 badane leczenie do czasu post\u0119pu choroby w\u202focenie radiologicznej, wyst\u0105pienia niedopuszczalnej toksyczno\u015bci, naruszenia protoko\u0142u, wycofania lub zako\u0144czenia badania. Czas udzia\u0142u w\u202fbadaniu MEVPRO-3 b\u0119dzie zale\u017cny od tolerancji badanego leczenia przez uczestnik\u00f3w lub od czasu do post\u0119pu choroby.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e7b51a elementor-widget elementor-widget-text-editor\" data-id=\"4e7b51a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tBadanie obejmuje 28-dniowy okres bada\u0144 przesiewowych, okres leczenia, okres obserwacji bezpiecze\u0144stwa trwaj\u0105cy 28\u201335\u202fdni oraz okres obserwacji d\u0142ugoterminowej.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-024c71f elementor-widget elementor-widget-text-editor\" data-id=\"024c71f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tOkres leczenia w\u202fbadaniu sk\u0142ada si\u0119 z cykli trwaj\u0105cych 4\u202ftygodnie (28\u202fdni). Uczestnicy odbywaj\u0105 wizyty co 4\u202ftygodnie do cyklu\u202f14 i\u202fnast\u0119pnie co 8\u202ftygodni podczas przyjmowania badanego leku. Uczestnicy b\u0119d\u0105 mieli wykonywane oceny obrazowe co 8\u202ftygodni do tygodnia\u202f25, a nast\u0119pnie co 12\u202ftygodni.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d537eca elementor-widget elementor-widget-text-editor\" data-id=\"d537eca\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Okres d\u0142ugoterminowej obserwacji bezpiecze\u0144stwa b\u0119dzie obejmowa\u0142 wizyty przeprowadzane co 8\u202ftygodni do tygodnia\u202f25, nast\u0119pnie co 12\u202ftygodni do zako\u0144czenia badania, co mo\u017ce trwa\u0107 wiele lat, lub do czasu wycofania zgody przez uczestnika.\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4445dbb5 e-con-full e-flex e-con e-parent\" data-id=\"4445dbb5\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-610b58e0 elementor-widget elementor-widget-text-editor\" data-id=\"610b58e0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tUczestnicy kwalifikuj\u0105cy si\u0119 do udzia\u0142u w badaniu \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5f8244e5 elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"5f8244e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"37\" height=\"38\" viewbox=\"0 0 37 38\" fill=\"none\"><path d=\"M35.8058 19.1635C35.8058 28.7761 28.0143 36.5685 18.4029 36.5685C8.79155 36.5685 1 28.7761 1 19.1635C1 9.55103 8.79155 1.75854 18.4029 1.75854\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M34.4319 4.04865L18.4029 23.5148L11.0753 17.5604\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Kluczowe kryteria w\u0142\u0105czenia:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3419d371 elementor-widget elementor-widget-text-editor\" data-id=\"3419d371\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li>Uczestnicy p\u0142ci m\u0119skiej w wieku \u2265 18 lat w momencie bada\u0144 przesiewowych.<\/li><li>Histologicznie lub cytologiczne potwierdzony gruczolakorak gruczo\u0142u krokowego bez cech drobnokom\u00f3rkowych.<\/li><li class=\"update-delete\">Choroba przerzutowa do ko\u015bci, potwierdzona w badaniu obrazowym ko\u015bci lub do tkanek mi\u0119kkich, potwierdzona w badaniu TK\/MRI.<\/li><li>Przerzutowy rak gruczo\u0142u krokowego udokumentowany dodatnim wynikiem badania obrazowego ko\u015bci (w przypadku choroby ko\u015bci) lub zmianami przerzutowymi w badaniu TK lub MRI (w przypadku choroby tkanek mi\u0119kkich\u202f\/\u202ftrzewi).\u202f<br \/><ul class=\"full-dot\"><li>Mierzalna choroba tkanek mi\u0119kkich\u202f\/\u202ftrzewi (zgodnie z\u202fkryteriami RECIST w wersji\u202f1.1) jest wymagana, je\u015bli nie ma mo\u017cliwej do oceny zmiany kostnej (zgodnie z\u202fkryteriami PCWG3).<\/li><li>W przypadku uczestnik\u00f3w z mierzaln\u0105 chorob\u0105 tkanek mi\u0119kkich sama choroba regionalnych w\u0119z\u0142\u00f3w ch\u0142onnych (np. poni\u017cej rozwidlenia aorty) nie kwalifikuje uczestnika do badania.<\/li><li>Badania PET i SPECT nie s\u0105 metodami obrazowania stosowanymi do oceny w tym badaniu.<\/li><li>Skan ko\u015bci wykazuj\u0105cy intensywn\u0105 symetryczn\u0105 aktywno\u015b\u0107 w ko\u015bciach (okre\u015blany jako superskan) nie jest uznawany za mo\u017cliwy do oceny.<\/li><\/ul><\/li><li>Uczestnicy musz\u0105 mie\u0107 wynik PS 0 lub 1 w skali sprawno\u015bci ECOG.<\/li><li>Uczestnicy nie mogli by\u0107 poddawani chemioterapii cytotoksycznej, leczeniu ARPI (np. enzalutamidem, apalutamidem, octanem abirateronu lub darolutamidem) ani innym og\u00f3lnoustrojowym terapiom przeciwnowotworowym mCSPC, z nast\u0119puj\u0105cymi wyj\u0105tkami:<br \/><ul class=\"full-dot\"><li>Terapia deprywacji androgen\u00f3w (ADT) (chemiczna lub chirurgiczna) musi zosta\u0107 rozpocz\u0119ta przed randomizacj\u0105 i by\u0107 kontynuowana przez ca\u0142y czas trwania badania. Wcze\u015bniejsza terapia deprywacji androgen\u00f3w trwaj\u0105ca do 3\u202fmiesi\u0119cy (z\u202fantyandrogenami lub bez) jest dozwolona bez radiograficznych dowod\u00f3w post\u0119pu choroby lub wzrostu poziomu PSA przed dniem\u202f1.<\/li><li>Leczenie estrogenami, octanem cyproteronu lub antyandrogenami pierwszej generacji jest dozwolone do momentu randomizacji, ale musi zosta\u0107 przerwane przed randomizacj\u0105.<\/li><li>Uczestnicy mogli przej\u015b\u0107 1\u202fcykl radioterapii paliatywnej lub zabieg chirurgiczny w celu kontroli objaw\u00f3w wt\u00f3rnych do raka gruczo\u0142u krokowego, kt\u00f3ry powinien zosta\u0107 zako\u0144czony co najmniej 2\u202ftygodnie przed randomizacj\u0105.<br \/>Uwaga: prostatektomia radykalna lub radioterapia definitywna guza pierwotnego gruczo\u0142u krokowego w\u202fprzypadku mCSPC z zamiarem wyleczenia nie jest dozwolona.<\/li><\/ul><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ffec70a elementor-widget elementor-widget-text-editor\" data-id=\"ffec70a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.elementor-element-ffec70a{display:none !important}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3253b30c elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"3253b30c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"38\" height=\"39\" viewbox=\"0 0 38 39\" fill=\"none\"><path d=\"M36.7946 19.2892C36.7946 29.4096 28.7624 37.5785 18.8973 37.5785C9.03215 37.5785 1 29.4096 1 19.2892C1 9.16892 9.03215 1 18.8973 1C28.7624 1 36.7946 9.16892 36.7946 19.2892Z\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M9.94592 9.64453L28.3459 28.9338\" stroke=\"#097900\" stroke-width=\"2\"><\/path><path d=\"M28.5946 9.89832L9.69731 28.6799\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Kluczowe kryteria wy\u0142\u0105czenia:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-39687a30 elementor-widget elementor-widget-text-editor\" data-id=\"39687a30\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li>Wcze\u015bniejsze stosowanie dowolnego z poni\u017cszych:<br \/><ul class=\"full-dot\"><li>ADT w leczeniu adiuwantowym\/neoadiuwantowym, gdzie ADT zako\u0144czono \u202f36\u202fmiesi\u0119cy.<\/li><li>ARPI, takie jak abirateron, apalutamid, darolutamid, enzalutamid lub inne badane ARPI.<\/li><li>Inhibitory enzymu cytochromu P17, takie jak doustny ketokonazol w leczeniu przeciwnowotworowym raka gruczo\u0142u krokowego.<\/li><li>Chemioterapia obejmuj\u0105ca docetaksel lub immunoterapia raka gruczo\u0142u krokowego.<\/li><li>Radiofarmaceutyki (tj. 177Lu-PSMA-617, rad-223).<\/li><li>Inhibitory CDK4\/6.<\/li><li>Jakiekolwiek inne leczenie przeciwnowotworowe przerzutowego raka gruczo\u0142u krokowego, z\u202fwy\u0142\u0105czeniem radioterapii paliatywnej\u202f\/\u202fzabiegu chirurgicznego i ADT, jak om\u00f3wiono powy\u017cej.<\/li><\/ul><\/li><li>Wyst\u0105pienie jakiegokolwiek innego raka w wywiadzie w ci\u0105gu ostatnich 3 lat (poza niekt\u00f3rymi nowotworami sk\u00f3ry lub nowotworami we wczesnym stadium, kt\u00f3re zosta\u0142y wyleczone).<\/li><li>Klinicznie istotna choroba uk\u0142adu sercowo-naczyniowego, choroba nerek lub choroba w\u0105troby.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2efc049 elementor-widget elementor-widget-text-editor\" data-id=\"2efc049\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.elementor-element-2efc049{display:none !important}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-51ce9c7 elementor-widget elementor-widget-text-editor\" data-id=\"51ce9c7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.elementor-element-51ce9c7{display:none !important}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6dbcba0 elementor-widget elementor-widget-text-editor\" data-id=\"6dbcba0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.elementor-element-6dbcba0{display:none !important}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-73e39f3 elementor-widget elementor-widget-text-editor\" data-id=\"73e39f3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.elementor-element-73e39f3{display:none !important}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bbaac08 elementor-widget elementor-widget-text-editor\" data-id=\"bbaac08\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li>Wcze\u015bniejsze stosowanie dowolnego z poni\u017cszych:<br \/><ul class=\"full-dot\"><li>ADT in the adjuvant\/neoadjuvant setting, where the completion of ADT was &lt;12 months prior to randomisation and the total duration of ADT was &gt;36 months.<\/li><li>ARPI, takie jak abirateron, apalutamid, darolutamid, enzalutamid lub inne badane ARPI.<\/li><li>Inhibitory enzymu cytochromu P17, takie jak doustny ketokonazol w leczeniu przeciwnowotworowym raka gruczo\u0142u krokowego.<\/li><li>Chemioterapia obejmuj\u0105ca docetaksel lub immunoterapia raka gruczo\u0142u krokowego.<\/li><li>Radiofarmaceutyki (tj. 177Lu-PSMA-617, rad-223).<\/li><li>Inhibitory CDK4\/6.<\/li><li>Jakiekolwiek inne leczenie przeciwnowotworowe przerzutowego raka gruczo\u0142u krokowego, z\u202fwy\u0142\u0105czeniem radioterapii paliatywnej\u202f\/\u202fzabiegu chirurgicznego i ADT, jak om\u00f3wiono powy\u017cej.<\/li><\/ul><\/li><li>Wyst\u0105pienie jakiegokolwiek innego raka w wywiadzie w ci\u0105gu ostatnich 3 lat (poza niekt\u00f3rymi nowotworami sk\u00f3ry lub nowotworami we wczesnym stadium, kt\u00f3re zosta\u0142y wyleczone).<\/li><li>Klinicznie istotna choroba uk\u0142adu sercowo-naczyniowego, choroba nerek lub choroba w\u0105troby.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-713f9797 e-flex e-con-boxed e-con e-parent\" data-id=\"713f9797\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2f78d127 elementor-widget elementor-widget-text-editor\" data-id=\"2f78d127\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Aby uzyska\u0107 informacje na temat wszystkich kryteri\u00f3w kwalifikacji, nale\u017cy porozmawia\u0107 z zespo\u0142em prowadz\u0105cym badanie lub przedstawicielem ds. medycznych firmy Pfizer.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-22c06a92 elementor-widget elementor-widget-text-editor\" data-id=\"22c06a92\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 600;\">Dzi\u0119kujemy za rozwa\u017cenie mo\u017cliwo\u015bci udzia\u0142u Pa\u0144stwa pacjent\u00f3w w tym badaniu klinicznym.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4990c650 elementor-align-right IDs-btn elementor-widget elementor-widget-button\" data-id=\"4990c650\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"closebtn\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#MEVPRO-3\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"42\" height=\"42\" viewbox=\"0 0 42 42\" fill=\"none\"><circle cx=\"21\" cy=\"21\" r=\"21\" fill=\"#097900\"><\/circle><path d=\"M13 24L21 16L29 24\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5958faa e-flex e-con-boxed e-con e-parent\" data-id=\"5958faa\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-a2b556e e-con-full e-flex e-con e-child\" data-id=\"a2b556e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-03d3426 elementor-widget elementor-widget-heading\" data-id=\"03d3426\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Czy maj\u0105 Pa\u0144stwo pod swoj\u0105 opiek\u0105 pacjent\u00f3w z przerzutowym rakiem gruczo\u0142u krokowego?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-1a9e3e1 e-con-full e-flex e-con e-child\" data-id=\"1a9e3e1\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-80251c2 e-con-full e-flex e-con e-child\" data-id=\"80251c2\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-24624e5 elementor-widget elementor-widget-image\" data-id=\"24624e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"77\" height=\"98\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/10\/medical-record-1.svg\" class=\"attachment-full size-full wp-image-455\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-151dd15 e-con-full e-flex e-con e-child\" data-id=\"151dd15\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-095411b elementor-widget elementor-widget-text-editor\" data-id=\"095411b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tTo learn more about Pfizer\u2019s MEVPRO Prostate Cancer Clinical Trials and how to refer potentially eligible patients, please complete the Contact Form and a member of the Pfizer Field Medical team will contact you. \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-dc65bb3 elementor-widget elementor-widget-button\" data-id=\"dc65bb3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"\/pl-pl\/hcp\/#contactform\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Contact Form<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-00be4aa e-flex e-con-boxed e-con e-parent\" data-id=\"00be4aa\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-21c39cd elementor-widget elementor-widget-heading\" data-id=\"21c39cd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Dzi\u0119kujemy za rozwa\u017cenie mo\u017cliwo\u015bci udzia\u0142u Pa\u0144stwa pacjent\u00f3w w badaniach klinicznych MEVPRO firmy Pfizer dotycz\u0105cych raka gruczo\u0142u krokowego.  <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-b188a5f e-flex e-con-boxed e-con e-parent\" data-id=\"b188a5f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-11a6f1c e-con-full e-flex e-con e-child\" data-id=\"11a6f1c\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d60c0ec elementor-widget elementor-widget-text-editor\" data-id=\"d60c0ec\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Jak dzia\u0142aj\u0105 badania kliniczne<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6bfe395 elementor-widget elementor-widget-image\" data-id=\"6bfe395\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"\/pl-pl\/clinical-trials\/\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"49\" height=\"49\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/09\/preFooter.svg\" class=\"attachment-large size-large wp-image-172\" alt=\"\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-572cd84 e-con-full e-flex e-con e-child\" data-id=\"572cd84\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-53bbb16 elementor-widget elementor-widget-text-editor\" data-id=\"53bbb16\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tKroki przyst\u0119powania do badania klinicznego\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a2e0214 elementor-widget elementor-widget-image\" data-id=\"a2e0214\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"\/pl-pl\/steps-to-join\/\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"49\" height=\"49\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/09\/preFooter.svg\" class=\"attachment-large size-large wp-image-172\" alt=\"\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-87bed07 e-con-full e-flex e-con e-child\" data-id=\"87bed07\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-94f0d2f elementor-widget elementor-widget-text-editor\" data-id=\"94f0d2f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tOchrona bezpiecze\u0144stwa i prywatno\u015bci\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2b7ca47 elementor-widget elementor-widget-image\" data-id=\"2b7ca47\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"\/pl-pl\/privacy\/\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"49\" height=\"49\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/09\/preFooter.svg\" class=\"attachment-large size-large wp-image-172\" alt=\"\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-b20ecc1 e-con-full e-flex e-con e-child\" data-id=\"b20ecc1\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e92688e elementor-widget-tablet__width-inherit elementor-widget elementor-widget-text-editor\" data-id=\"e92688e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tCz\u0119sto zadawane pytania\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-61b0a47 elementor-widget elementor-widget-image\" data-id=\"61b0a47\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"\/pl-pl\/faq\/\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"49\" height=\"49\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/09\/preFooter.svg\" class=\"attachment-large size-large wp-image-172\" alt=\"\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Pfizer MEVPRO Prostate Cancer Clinical Trials Help advance metastatic prostate cancer treatment research Explore Pfizer\u2019s MEVPRO Clinical Trials as potential options for your patients Not yet recruiting Recruiting MEVPRO-1For your patients with abiraterone-resistant metastatic prostate cancer Clinicaltrials.gov Clinicaltrialsregister.eu A Phase 3 clinical trial evaluating the investigational medicine (mevrometostat) in combination with enzalutamide compared to enzalutamide [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"single_temp_hcp_trial.php","meta":{"footnotes":""},"class_list":["post-360","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/mevproclinicaltrials.com\/pl-pl\/wp-json\/wp\/v2\/pages\/360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mevproclinicaltrials.com\/pl-pl\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/mevproclinicaltrials.com\/pl-pl\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/mevproclinicaltrials.com\/pl-pl\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mevproclinicaltrials.com\/pl-pl\/wp-json\/wp\/v2\/comments?post=360"}],"version-history":[{"count":0,"href":"https:\/\/mevproclinicaltrials.com\/pl-pl\/wp-json\/wp\/v2\/pages\/360\/revisions"}],"wp:attachment":[{"href":"https:\/\/mevproclinicaltrials.com\/pl-pl\/wp-json\/wp\/v2\/media?parent=360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}